Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analyst consensus: 21 brokerages rate Axsome an average "Moderate Buy" (18 buys, 2 sells, 1 strong buy) with a one‑year average price target of about $235.79.
• Q1 results mixed: Revenue rose 57% YoY to $191.2M, essentially matching Street expectations, but GAAP EPS missed at -$1.26 versus a -$0.85 consensus, highlighting continued negative margins and near‑term profitability pressure.
• Pipeline and regulatory catalysts: AUVELITY gained approval for agitation in dementia due to Alzheimer’s, an NDA for AXS‑12 was submitted, and AXS‑20 was added to the pipeline, supporting potential upside beyond current products.

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twenty-one brokerages that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eighteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $235.7895.

A number of analysts recently commented on the stock. Leerink Partners boosted their price objective on shares of Axsome Therapeutics from $150.00 to $205.00 and gave the stock an "outperform" rating in a report on Wednesday, January 28th. HC Wainwright upped their target price on Axsome Therapeutics from $260.00 to $270.00 and gave the company a "buy" rating in a report on Monday. Royal Bank Of Canada raised their price objective on shares of Axsome Therapeutics from $219.00 to $222.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 24th. TD Cowen reissued a "buy" rating on shares of Axsome Therapeutics in a research note on Friday. Finally, Wells Fargo & Company raised their price target on shares of Axsome Therapeutics from $193.00 to $202.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 24th.

Axsome Therapeutics Stock Up 8.5%

AXSM opened at $224.03 on Tuesday. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.55 and a quick ratio of 1.48. Axsome Therapeutics has a 12 month low of $96.09 and a 12 month high of $234.29. The stock has a market capitalization of $11.52 billion, a P/E ratio of -60.71 and a beta of 0.59. The business has a 50 day simple moving average of $170.95 and a 200-day simple moving average of $162.68.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings data on Monday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.41). Axsome Therapeutics had a negative return on equity of 232.61% and a negative net margin of 28.69%.The business had revenue of $191.20 million during the quarter, compared to analysts' expectations of $191.10 million. The company's revenue for the quarter was up 57.4% compared to the same quarter last year. On average, equities analysts anticipate that Axsome Therapeutics will post -1.06 earnings per share for the current fiscal year.

More Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Q1 revenue strength: Total net product revenue grew 57% YoY to $191.2M, with AUVELITY at $153.2M (up 59% YoY), SUNOSI $33.9M (up 34% YoY) and SYMBRAVO $4.1M — a concrete sales beat/acceleration story driving investor optimism. GlobeNewswire: Q1 2026 Results
• Positive Sentiment: Regulatory and pipeline catalysts: AUVELITY gained an approval for agitation associated with dementia due to Alzheimer’s; an NDA for AXS-12 (cataplexy) was submitted; and AXS-20 (pre‑Phase 3 PDE10A) was added to the pipeline — news that supports upside potential beyond current products. GlobeNewswire: Pipeline Update
• Neutral Sentiment: Quarter versus expectations: Reported revenue basically matched Street consensus ($191.20M vs $191.22M), so the topline validated growth but did not materially exceed expectations. MarketBeat: Q1 Summary & Materials
• Neutral Sentiment: Investor materials available: Management hosted a call and released slides (useful for modeling adoption/launch cadence and guidance commentary). Review transcripts and slides for management’s cadence on launch trends and expenses. Seeking Alpha: Earnings Call Transcript
• Negative Sentiment: EPS miss and profitability pressure: GAAP EPS was a loss of $1.26 vs consensus -$0.85, widening the loss and underscoring ongoing negative margins and high R&D/SG&A investment that pressure near-term earnings. Zacks: Q1 Loss & Revenue
• Negative Sentiment: Sequential softness and skeptical analyst tone: Some write-ups note sequential declines in AUVELITY and SUNOSI sales and call management’s peak revenue targets (multi‑$B across portfolio) ambitious — raising questions about sustainability and competitive pressures. Analysts are mixed/neutral (some maintain Hold). Seeking Alpha: Q1 Review

Insiders Place Their Bets

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 35,378 shares of the stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $161.88, for a total transaction of $5,726,990.64. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Mark Coleman sold 25,000 shares of the stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $161.11, for a total transaction of $4,027,750.00. Following the sale, the director directly owned 47,140 shares of the company's stock, valued at approximately $7,594,725.40. This trade represents a 34.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 67,878 shares of company stock valued at $11,122,891. Insiders own 20.60% of the company's stock.

Institutional Investors Weigh In On Axsome Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Kemnay Advisory Services Inc. bought a new position in Axsome Therapeutics during the 4th quarter valued at $31,000. Ameriflex Group Inc. bought a new stake in shares of Axsome Therapeutics during the 4th quarter valued at about $37,000. Versant Capital Management Inc boosted its holdings in shares of Axsome Therapeutics by 20,300.0% during the third quarter. Versant Capital Management Inc now owns 204 shares of the company's stock valued at $25,000 after acquiring an additional 203 shares during the period. GAMMA Investing LLC boosted its stake in Axsome Therapeutics by 65.4% during the 4th quarter. GAMMA Investing LLC now owns 268 shares of the company's stock valued at $49,000 after purchasing an additional 106 shares during the period. Finally, Farther Finance Advisors LLC lifted its holdings in Axsome Therapeutics by 602.6% in the fourth quarter. Farther Finance Advisors LLC now owns 274 shares of the company's stock worth $50,000 after purchasing an additional 235 shares during the period. 81.49% of the stock is owned by institutional investors and hedge funds.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome's pipeline includes several late-stage and approved product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.